Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6058547 | 0.88 | EPHX1 (0.53) | TSHREPHX2GAAEPHX1LMNA | |
| SCHEMBL733617 | 0.83 | EPHX2 (0.62) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12858009 | 0.83 | EPHX2 (0.57) | TSHREPHX2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL5608005 | 0.81 | TSHR (0.47) | TSHREPHX2GAAEPHX1KMT2A | |
| SCHEMBL6228020 | 0.81 | GRIN2D (0.48) | TSHREPHX2GAAEPHX1LMNA | |
| SCHEMBL14572512 | 0.81 | TSHR (0.60) | TSHREPHX2GAAEPHX1GRIN2D | |
| SCHEMBL29602546 | 0.81 | TSHR (0.47) | TSHREPHX2GAAEPHX1KMT2A | |
| SCHEMBL28098358 | 0.81 | TSHR (0.49) | TSHREPHX2GAAEPHX1LMNA | |
| SCHEMBL3821518 | 0.81 | TSHR (0.54) | TSHREPHX2GAAEPHX1GRIN2D | |
| SCHEMBL6058450 | 0.80 | TSHR (0.46) | TSHREPHX2GAAEPHX1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1999100-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-12-10 | — | — | EP | claimed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2007126886-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICALS USA, INC. (US) | 2007-11-08 | — | — | WO | claimed |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-4209494-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | Fujian Akeylink Biotechnology Co., Ltd. (CN) | 2023-07-12 | — | — | EP | disclosed |
| US-8481016-B2 | Method for inhibition of potential-dependent cation channel | KAO CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| EP-2373612-B1 | METHOD FOR PRODUCING MEMANTINE | MERZ PHARMA GMBH & CO KGAA (DE) | 2013-04-17 | — | — | EP | disclosed |
| US-20130045177-A1 | Method for Inhibition of Potential-Dependent Cation Channel | KAO CORPORATION (JP) | 2013-02-21 | — | — | US | disclosed |
| EP-1999100-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-12-10 | — | — | EP | disclosed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2007126886-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICALS USA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007126886-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICALS USA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045177-A1 | Method for Inhibition of Potential-Dependent Cation Channel | TRPM7, TRPM8, OR10J3 | TSHR 1275/4885EPHX2 1636/4885GAA 4162/4885 |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | VIP, PREP, PRAP1 | TSHR 3278/4885EPHX2 3187/4885GAA 2237/4885 |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | PNMT, PSEN2, CHRNA5 | TSHR 3555/4885EPHX2 2141/4885GAA 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.